Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 11,110,200 | 10,151,100 | 9,289,900 | 10,504,000 | 9,171,500 |
| Marketable Securities | 818,000 | 1,085,200 | 1,124,200 | 274,500 | 599,200 |
| Receivables | 1,538,700 | 1,556,200 | 1,547,800 | 1,442,200 | 1,385,200 |
| Inventories | 688,700 | 603,500 | 535,100 | 460,600 | 388,200 |
| TOTAL | $14,695,800 | $13,872,900 | $12,965,700 | $13,234,800 | $12,271,000 |
| Non-Current Assets | |||||
| PPE Net | 1,124,000 | 1,122,400 | 1,111,700 | 1,108,400 | 1,118,700 |
| Investments And Advances | 1,700,000 | 1,357,300 | 1,081,500 | 112,200 | 0 |
| Intangibles | 1,691,600 | 1,691,600 | 1,691,600 | 1,691,600 | 1,678,800 |
| Other Non-Current Assets | 2,514,800 | 2,305,000 | 2,123,700 | 2,003,900 | 1,637,900 |
| TOTAL | $7,030,400 | $6,476,300 | $6,008,500 | $4,916,100 | $4,435,400 |
| Total Assets | $21,726,200 | $20,349,200 | $18,974,200 | $18,150,900 | $16,706,400 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 375,900 | 363,000 | 323,200 | 303,900 | 126,900 |
| Accrued Expenses | 2,907,300 | 2,598,100 | 2,326,000 | 2,126,700 | 2,264,400 |
| Other current liabilities | 316,200 | 391,000 | 377,000 | 311,500 | 218,000 |
| TOTAL | $3,599,400 | $3,352,100 | $3,026,200 | $2,742,100 | $2,609,300 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,223,700 | 1,122,800 | 1,098,100 | 1,065,300 | 625,200 |
| TOTAL | $1,614,000 | $1,526,900 | $1,515,700 | $1,496,100 | $1,067,500 |
| Total Liabilities | $5,213,400 | $4,879,000 | $4,541,900 | $4,238,200 | $3,676,800 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 257,683 | 258,095 | 257,552 | 257,091 | 256,692 |
| Common Shares | 2,600 | 2,600 | 2,600 | 2,600 | 2,600 |
| Retained earnings | 9,173,600 | 8,138,300 | 7,222,600 | 6,522,800 | 5,703,900 |
| Other shareholders' equity | -3,000 | -39,800 | -13,100 | 800 | 97,600 |
| TOTAL | $16,512,800 | $15,470,200 | $14,432,300 | $13,912,700 | $13,029,600 |
| Total Liabilities And Equity | $21,726,200 | $20,349,200 | $18,974,200 | $18,150,900 | $16,706,400 |